文献速递临床试验与 GCP流行病学与生物统计

醋酸阿比特龙联合泼尼松龙联合或不联合恩扎卢胺治疗高危非转移性前列腺癌:STAMPEDE平台方案两项随机对照3期试验主要结果的Meta分析

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
PubMed 文献 · Lancet · 2021-12-23

两项开放标签3期试验共纳入1974例高危非转移性前列腺癌患者,比较ADT联合阿比特龙+泼尼松龙(联合或不联合恩扎卢胺)与ADT单药的疗效。中位随访72个月,联合治疗组无转移生存显著优于对照组(HR 0.53,95%CI 0.44-0.64,p<0.0001),6年无转移生存率分别为82%和69%。作者认为阿比特龙+泼尼松龙应被视为该人群的新标准治疗。

要点

  • 联合治疗组无转移生存显著优于对照组(HR 0.53,95%CI 0.44-0.64,p<0.0001)
  • 6年无转移生存率联合治疗组82% vs 对照组69%
  • 联合治疗组3级及以上不良事件发生率高于对照组

核心结论

  • 在高危非转移性前列腺癌男性中,联合治疗与ADT单药相比无转移生存率显著更高。
  • 作者认为醋酸阿比特龙联合泼尼松龙应被视为该人群的新标准治疗。

研究设计与样本

  • 开放标签、3期随机对照试验,在英国和瑞士113个中心开展,采用多臂多阶段平台方案。
  • 共1974例患者随机分配:第一项试验对照组455例、联合治疗组459例;第二项试验(含恩扎卢胺)对照组533例、联合治疗组527例。
  • 入组时间为2011年11月15日至2016年3月31日,中位年龄68岁(IQR 63-73),中位PSA 34 ng/ml(14.7-47)。
  • 774例(39%)为淋巴结阳性,1684例(85%)计划接受放疗。
  • 本Meta分析采用Meta分析方法合并两项试验的事件,主要终点为无转移生存。

主要发现

  • 中位随访72个月(60-84),联合治疗组无转移生存事件180例,对照组306例。
  • 无转移生存联合治疗组显著更长(中位未达到,IQR不可评估[NE]-NE)vs 对照组(未达到,97-NE;HR 0.53,95%CI 0.44-0.64,p<0.0001)。
  • 6年无转移生存率联合治疗组82%(95%CI 79-85)vs 对照组69%(66-72)。
  • 总生存联合治疗组中位未达到(IQR NE-NE)vs 对照组未达到(103-NE;HR 0.60,95%CI 0.48-0.73,p<0.0001)。
  • 前列腺癌特异性生存联合治疗组未达到(NE-NE)vs 对照组未达到(NE-NE;HR 0.49,95%CI 0.37-0.65,p<0.0001)。

临床怎么用

  • 作者认为醋酸阿比特龙联合泼尼松龙应被视为高危非转移性前列腺癌的新标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population. METHODS: These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8-10, and prostate-specific antigen [PSA] concentration ≥40 ng/mL) or relapsing with high-risk features (≤12 months of total ADT with an interval of ≥12 months without treatment and PSA concentration ≥4 ng/mL with a doubling time of <6 months, or a PSA concentration ≥20 ng/mL, or nodal relapse) non-metastatic prostate cancer, and a WHO performance status of 0-2. Local radiotherapy (as per local guidelines, 74 Gy in 37 fractions to the prostate and seminal vesicles or the equivalent using hypofractionated schedules) was mandated for node negative and encouraged for node positive disease. In both trials, patients were randomly assigned (1:1), by use of a computerised algorithm, to ADT alone (control group), which could include surgery and luteinising-hormone-releasing hormone agonists and antagonists, or with oral abiraterone acetate (1000 mg daily) and oral prednisolone (5 mg daily; combination-therapy group). In the second trial with no overlapping controls, the combination-therapy group also received enzalutamide (160 mg daily orally). ADT was given for 3 years and combination therapy for 2 years, except if local radiotherapy was omitted when treatment could be delivered until progression. In this primary analysis, we used meta-analysis methods to pool events from both trials. The primary endpoint of this meta-analysis was metastasis-free survival. Secondary endpoints were overall survival, prostate cancer-specific survival, biochemical failure-free survival, progression-free survival, and toxicity and adverse events. For 90% power and a one-sided type 1 error rate set to 1·25% to detect a target hazard ratio for improvement in metastasis-free survival of 0·75, approximately 315 metastasis-free survival events in the control groups was required. Efficacy was assessed in the intention-to-treat population and safety according to the treatment started within randomised allocation. STAMPEDE is registered with ClinicalTrials.gov, NCT00268476, and with the ISRCTN registry, ISRCTN78818544. FINDINGS: Between Nov 15, 2011, and March 31, 2016, 1974 patients were randomly assigned to treatment. The first trial allocated 455 to the control group and 459 to combination therapy, and the second trial, which included enzalutamide, allocated 533 to the control group and 527 to combination therapy. Median age across all groups was 68 years (IQR 63-73) and median PSA 34 ng/ml (14·7-47); 774 (39%) of 1974 patients were node positive, and 1684 (85%) were planned to receive radiotherapy. With median follow-up of 72 months (60-84), there were 180 metastasis-free survival events in the combination-therapy groups and 306 in the control groups. Metastasis-free survival was significantly longer in the combination-therapy groups (median not reached, IQR not evaluable [NE]-NE) than in the control groups (not reached, 97-NE; hazard ratio [HR] 0·53, 95% CI 0·44-0·64, p<0·0001). 6-year metastasis-free survival was 82% (95% CI 79-85) in the combination-therapy group and 69% (66-72) in the control group. There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone acetate alone (interaction HR 1·02, 0·70-1·50, p=0·91) and no evidence of between-trial heterogeneity (I2 p=0·90). Overall survival (median not reached [IQR NE-NE] in the combination-therapy groups vs not reached [103-NE] in the control groups; HR 0·60, 95% CI 0·48-0·73, p<0·0001), prostate cancer-specific survival (not reached [NE-NE] vs not reached [NE-NE]; 0·49, 0·37-0·65, p<0·0001), biochemical failure-free-survival (not reached [NE-NE] vs 86 months [83-NE]; 0·39, 0·33-0·47, p<0·0001), and progression-free-survival (not reached [NE-NE] vs not reached [103-NE]; 0·44, 0·36-0·54, p<0·0001) were also significantly longer in the combination-therapy groups than in the control groups. Adverse events grade 3 or higher during the first 24 months were, respectively, reported in 169 (37%) of 451 patients and 130 (29%) of 455 patients in the combination-therapy and control groups of the abiraterone trial, respectively, and 298 (58%) of 513 patients and 172 (32%) of 533 patients of the combination-therapy and control groups of the abiraterone and enzalutamide trial, respectively. The two most common events more frequent in the combination-therapy groups were hypertension (abiraterone trial: 23 (5%) in the combination-therapy group and six (1%) in control group; abiraterone and enzalutamide trial: 73 (14%) and eight (2%), respectively) and alanine transaminitis (abiraterone trial: 25 (6%) in the combination-therapy group and one (<1%) in control group; abiraterone and enzalutamide trial: 69 (13%) and four (1%), respectively). Seven grade 5 adverse events were reported: none in the control groups, three in the abiraterone acetate and prednisolone group (one event each of rectal adenocarcinoma, pulmonary haemorrhage, and a respiratory disorder), and four in the abiraterone acetate and prednisolone with enzalutamide group (two events each of septic shock and sudden death). INTERPRETATION: Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population. FUNDING: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2021. PMID: 34953525. doi:10.1016/S0140-6736(21)02437-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。